From £6.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Each morning, I am disappointed by Shield Therapeutics

By Tom Winnifrith | Sunday 12 June 2022


Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


On February 18, I generated industrial-scale abuse (of me) from anonymous internet warriors. All I did was suggest Shield Therapeutics (STX) as a slam-dunk short, at 25.5p.  The savants insisted, as is usually the case in such circumstances, that I didn’t understand the maths, and should go back to working in a pizza store, etc, etc, etc. The shares are now just 14.6p, and the final collapse is almost upon us. Add to your shorts. Let me explain.

Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

PICH

Pitch Pit – this stinks

 

GEX

Georgina Energy: Lyin’ Yet again

Time left: 22:55:12